Advertisement

Preactivation-Discovery and Biological Effects of Novel Chemotherapeutic Agents

  • Kirpal S. Gulliya
Chapter
  • 19 Downloads
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

As an immunologist, my research interests had been focused on immunotherapy of cancer involving monoclonal antibodies as a mode of drug delivery and cytokines as therapeutic agents. I had no real interest or in-depth understanding of photobiology until September 1986, when I joined the Baylor Research Foundation (now Baylor Research Institute) where several photobiology related projects were already in progress. In one of these projects lead by Dr. Lester Matthews, it was demonstrated that in vivo chloroquine resistant parasitemia caused by P. berghei (resistant to at least three daily doses of 0.4 mg/kg of chloroquine) could be significantly reduced when treated with hematoporphyrin derivative (HPD) prior to chloroquine injection.1 Therefore, the following question was asked; if HPD plus chloroquine = death of the parasite, then what other compound (say X) plus HPD will induce death in tumor cells? Finding the answer to this question was one of my research projects, and it involved the determination of the dark toxicity of HPD in the presence of compound X against cultured tumor cells. This was the beginning of my inculcation into the field of photo-dynamic therapy.

Keywords

Photodynamic Therapy Simian Immunodeficiency Virus Human Peripheral Blood Mononuclear Cell Tiaprofenic Acid Culture Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sogandares-Bernal F, Matthews JL, Judy MM. HPD-induced reversal of chloroquine resistance of malaria. Mem Inst Oswaldo Cruz, Rio de Janeiro, 1986; 81: 241–50.CrossRefGoogle Scholar
  2. 2.
    Salama G, and Murad M. Merocyanine 540 as an optical probe of transmembrane electrical activity in the heart. Science 1976; 191: 485–87.PubMedCrossRefGoogle Scholar
  3. 3.
    Atzpodien J, Gulati SC, Clarkson BD. Comparison of cytotoxic effects of merocyanine 540 on leukemic cells and human bone marrow. Cancer Res 1986; 46: 4892–94.PubMedGoogle Scholar
  4. 4.
    Sieber F. Marrow purging by merocyanine 540 mediated photolysis. Bone Marrow Transplantation. Proceedings of the First International Workshop on Bone Marrow Purging 1987; 2:(Suppl. 2)29–33.Google Scholar
  5. 5.
    Gulliya KS, Pervaiz S. Elimination of clonogenic tumor stem cells from HL-60, Daudi and U-937 cell lines by laser photoradiation therapy: Implication for A bone marrow purging. Blood 1989; 73: 1059–1065.PubMedGoogle Scholar
  6. 6.
    Gulliya K, Fay J, Dowben R et al. Elimination of leukemic cells by photodynamic therapy. Cancer Chemother Pharmacol 1988; 22: 211–14.PubMedCrossRefGoogle Scholar
  7. 7.
    Gulliya K, Matthews J, Fay J et al. Increased survival of bone marrow cells during laser light induced photosensitization: Implications for ex vivo bone marrow purging. Life Sci 1988; 112: 2651–56.CrossRefGoogle Scholar
  8. 8.
    Gulliya KS. An in vitro model of autologous bone marrow purging for multiple myeloma and lung carcinoma cells by laser photo-radiation therapy. Cancer J 1989; 2: 378–82.Google Scholar
  9. 9.
    Gulliya KS, Battaglino M. Breast cancer and laser photoradiation therapy: An in vitro model of autologous bone marrow purging. In: Gross S, Gee AP, Worthington-White DA, eds. Prog Clin Biol Res. New York: Wiley-Liss, 1989: 133: 103–107.Google Scholar
  10. 10.
    Chan WS, Sevenson R, Phillips D et al. Cell uptake, distribution and response to aluminumchloro sulfonated phthalocyanine: a potential antitumor photosensitizer. Br J Cancer 1986; 53: 255–63.PubMedCrossRefGoogle Scholar
  11. 11.
    van Lier JE, Spikes JD. The chemistry, photophysics and photosensitizing properties of of phthalocyanines. In: Bock G, Harnett Wiley S, eds. Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use. Chichester: Ciba Foundation, 1989: 146: 17–26.Google Scholar
  12. 12.
    Rosenthal I, Murali Krishna C, Risez P et al. The role of molecular oxygen in the photodynamic effect of phthalocyanines. Radiat Res 1986; 107: 136–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in the inactivation of a murine tumor. Cancer Res 1976; 36: 2326–29.PubMedGoogle Scholar
  14. 14.
    Moan J. On the diffusion length of singlet oxygen in cells and tissues. J Photochem Photobiol B Biol 1990, 6: 343–44.CrossRefGoogle Scholar
  15. 15.
    Davila J, Harriman A, Gulliya KS et al. Photochemistry of merocyanine 540: The mechanism of chemotherapeutic activity with cyanine dyes. Photochem Photobiol 1991; 53: 1–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Longo DL. Lung Cancer: The (red) light at the end of tunnel? Abstract and commentary. Clinical Oncology Alert 1993; 8: 91–92.Google Scholar
  17. 17.
    Chang Po-H, Pervaiz S, Battaglino M et al. Synergistic effect of preactivated photofrin-II and tamoxifen in killing retrofibroma pseudomyxoma and breast cancer cells. Eur J Cancer 1991; 28: 1034–39.Google Scholar
  18. 18.
    Gulliya KS, Pervaiz S, Dowben et al. Tumor cell specific dark cytotoxicity of light-exposed merocyanine 540: Implications for systemic therapy without light. Photochem Photobiol 1990; 51: 831–38.CrossRefGoogle Scholar
  19. 19.
    Singh RJ, Feix JB, Kalyanaraman B. Photobleaching of merocyanine 540: involvement of singlet molecular oxygen. Photochem Photobiol 1992; 55: 483–89.PubMedCrossRefGoogle Scholar
  20. 20.
    Spikes JD. Quantum yields and kinetics of the photobleaching of hematoporphyrin, photofrin II, tetra (4-sulfonatophenyl)-porphine and uroporphyrin. Photochem Photobiol 1992; 55: 797–808.PubMedCrossRefGoogle Scholar
  21. 21.
    Castell JV, Gomez-Lechon MJ, Grassa C et al. Involvement of drug-derived peroxides in the phototoxicity of naproxen and tiaprofenic acid. Photochem Photobiol 1993; 57: 486–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Ashwood-Smith MJ, Ceska O, Warrington PJ et al.The photobiological activity of 5-geranoxypsoralen and its photoproducts. Photochem Photobiol 1992; 55: 529–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Franck B, Schneider U. Photooxidation products of merocyanine 540 formed under preactivation conditions for tumor therapy. Photochem Photobiol 1992; 56: 271–76.PubMedCrossRefGoogle Scholar
  24. 24.
    Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461–63.PubMedCrossRefGoogle Scholar
  25. 25.
    Salmon SE, Hamburger AW, Soehnlen B et al. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Eng J Med 1978; 298: 1312–27.CrossRefGoogle Scholar
  26. 26.
    Shoemaker RH, Wolpert-Defillipes MK, Kern DH et. al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2145–53.PubMedGoogle Scholar
  27. 27.
    Blough HA, Tiffany JM, eds. Cell Membranes and Viral Envelopes. New York: Academic Press, 1980; 2: 459–518.Google Scholar
  28. 28.
    Barnhart ER, Ash RJ. Similarities and differences between viral and cellular membranes. Prog Med Virol 1979; 25: 89–112.PubMedGoogle Scholar
  29. 29.
    Chanh TC, Allan JS, Pervaiz S. Preactivated merocyanine 540 inactivates HIV-1 and SIV: Potential therapeutic and blood banking applications. J AIDS 1992; 5: 188–95.Google Scholar
  30. 30.
    Inbar M, Sachs L. Interaction of the carbohydrate-binding protein concanavalin A with normal and transformed cells. Proc Nat Acad Sci USA 1969; 63: 1418–25.PubMedCrossRefGoogle Scholar
  31. 31.
    Hakamori S, Teather C, Andrews HD. Biochem Biophys Res Commun 1968; 33. 563–68.CrossRefGoogle Scholar
  32. 32.
    Hakomori S, Teather C, Andrews HD. Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc Natl Acad Sci USA 1968; 59: 254–261.PubMedCrossRefGoogle Scholar
  33. 33.
    Critchley DR, Macpherson I. Cell density dependent glycolipids in NILz hamster cells. Biochem Biophys Acta 1973; 296: 145–59.PubMedCrossRefGoogle Scholar
  34. 34.
    Grimes WJ. Glycosyltransferase and sialic acid levels of normal and transformed cells. Biochemistry 1973; 12: 990–96.PubMedCrossRefGoogle Scholar
  35. 35.
    Warren L, Fuhrer JB, Buck CA. Surface glycoproteins of normal and transformed cells: a difference determined by sialic acid and a growth-dependent sialyl transferase. Proc Nat Acad Sci USA 1972; 69: 1838–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Klein G. Tumor-specific transplantation antigens: G. H. A Clowes memorial lecture (Review).Cancer Res 1968; 28: 625–35.Google Scholar
  37. 37.
    Allan JS, Strauss J, Buck DW. Enhancement of SIV infection with soluble receptor molecules. Science 1990; 247: 1084–88.PubMedCrossRefGoogle Scholar
  38. 38.
    Moore JP, McKeating JA, Weiss, RA. Dissociation of gp 120 from HIV-1 virions induced by soluble CD4. Science 1990; 250: 1139–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Kirpal S. Gulliya
    • 1
    • 2
    • 3
  1. 1.Baylor Research InstituteBaylor University Medical CenterDallasUSA
  2. 2.Institute of Biomedical StudiesBaylor UniversityWacoUSA
  3. 3.Department of Biological ScienceUniversity of North TexasDentonUSA

Personalised recommendations